What happened: Novo Nordisk, maker of the weight-loss drug Wegovy, has warned that price reductions will be challenging for the company amid rising competition and expiring patents. The announcement led to a significant drop in the firm's share price.
Why it matters:
- Price pressures could reduce Novo Nordisk's revenues and profits.
- Patients and healthcare providers may see changes in drug availability or pricing.
MNN Take: The company is facing a tough market environment with more competitors entering and key patents ending, which typically leads to lower prices and increased pressure on profits.
Sources: BBC Business